New Delhi: The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) have recommended 16 proposals of devices, diagnostics, vaccine candidates, therapeutics and other interventions for receiving funding support.
The process of such recommendation followed after 500 applications from academia and Industry have been thoroughly reviewed.
According to government officials, a multifaceted approach is being adopted to ensure that vaccine candidates utilizing different platforms and at different stages of development are fast-tracked through this Research Consortium under funding from National Biopharma Mission.
Both, repurposing of existing vaccine candidates for immediate protection of high-risk groups and novel vaccine candidate development were considered while selecting proposals under this call.
Funding support has been recommended to Cadila Healthcare Ltd for advancing the development of a DNA Vaccine candidate against Novel Coronavirus SARS-CoV-2. and to Bharat Biotech International Ltd for COVID-19 vaccine candidate utilising their activated rabies vector platform, officials said.
Furthermore, for the Phase III human clinical trials study of the recombinant BCG vaccine (VPM1002) planned in the high-risk populations, Serum Institute of India Private Limited (SIIPL) will be supported. The development of a novel vaccine evaluation platform at the National Institute of Immunology to support SARS-CoV-2 vaccine development has also been approved for financial support, officials added.
Production of purified immunoglobulin G, IgG, at commercial scale from COVID-19 convalescent sera and production of high titers of equine hyperimmune globulin for the treatment of COVID infected patients on large scale will be supported at Virchow Biotech Pvt Ltd. Financial support to OncoSeek Bio Pvt Ltd will be provided to create an in vitro Lung Organoid model, officials said.
To boost indigenous production and to scale-up, the production of molecular and Rapid diagnostic tests following companies will receive financial support: Mylab Discovery Solutions Pvt Ltd, Huwel Lifesciences, Ubio Biotechnology Systems Pvt Ltd, Dhiti Life Sciences Pvt Ltd, MagGenome Technologies Pvt Ltd, Bigtec Pvt Ltd, and Yaathum Biotech Pvt Ltd.
Commonly shared facility to manufacture diagnostic kits and ventilators will be established at Andhra Pradesh MedTech Zone (AMTZ) under the National Biopharma Mission of DBT to provide scale up production capacity to different manufacturers.
Also Read: Plea in SC seeks reduction in non COVID-19 medical treatment
